XOMA Makes Cost-Cutting Move by Restructuring Novartis Deal

By Helen Scrutton

Pharma Deals Review: Vol 2008 Issue 102 (Table of Contents)

Published: 10 Nov-2008

DOI: 10.3833/pdr.v2008.i102.108     ISSN: 1756-7874

Section: Licensing



XOMA is the latest in a long line of companies forced to relinquish development programmes in order to save money...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details